We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Arterial and Cardiac Clots Found Similar

By HospiMedica staff writers
Posted on 08 Sep 2006
A new study shows that contrary to traditional beliefs, stroke-causing clots derived from arterial and cardiac sources are composed of similar components. More...


Researchers from the University of California, Los Angeles (UCLA, USA), studied clots removed from the brain blood vessels of 25 stroke victims. The clots were retrieved during treatment using a novel mechanical clot-retrieval device called the MERCI (mechanical embolus removal in cerebral ischemia) retriever. The removed clots were analyzed under the microscope to compare their component structures.

Unexpectedly, no two retrieved clots looked the same, but the large majority (75%) of thromboemboli shared architectural features of random fibrin: platelet deposits interspersed with linear collections of nucleated cells (monocytes and neutrophils) and confined erythrocyte-rich regions. The same components were involved in both the newly formed and mature clots. While red blood-cell accumulations had previously been considered to dominate the structure of clots that formed within a heart chamber, the new results suggest that red cells often accumulate on clots after impaction in the brain artery. The findings were reported in the June 29, 2006, online issue of the journal Stroke.

"This could potentially change the way we treat clots,” said co-author Dr. Jeffrey Saver, professor of neurology at the David Geffen School of Medicine at UCLA and co-director of the UCLA Stroke Center. "Now that we can retrieve clots, we can analyze their molecular composition and determine the combination of mechanical therapies and clot-dissolving agents most likely to allow us to open up arteries.”

The MERCI retriever, which allows removal and analysis of clots within six hours of symptoms onset, was invented at UCLA and sponsored by Concentric Medical (Mountain View, CA, USA). The U.S. Food and Drug Administration (FDA) approved the MERCI Retriever in 2004 for removal of clots from brain arteries in patients experiencing ischemic stroke within the first eight hours of stroke onset.



Related Links:
University of California Los Angeles
Concentric Medical

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.